Propanc Biopharma Inc (PPCB)

[swamp-rat]

Biotech's Leading the way in Life Altering Cancer Therapies
20 minutes ago - DJNF
Microcapspeculators.com News Commentary

LAS VEGAS, September 20, 2017 /PRNewswire/ --

Over the course of the last few years we have seen significant gains in life changing cancer therapies. These gains in cancer science are set to continue to be more frequent, and significant. Biotechnology companies that are focused on this incredibly large, and needed market of cancer drugs are going to reap the benefits. According to Zion Market Research the Global cancer market is set to reach $161.30 Billion by 2021. Biotech companies involved in the cancer treatment market, that everyone should take notice of immediately include:Propanc Biopharma, Inc. (OTC: PPCB), Kura Oncology, Inc. (NASDAQ: KURA), NewLink Genetics Corporation (NASDAQ: NLNK), Stemline Therapeutics, Inc. (NASDAQ: STML), and Verastem, Inc. (NASDAQ: VSTM).

Propanc Biopharma, Inc. (OTCQB: PPCB)

Market Cap: $1.45M, Current Share Price: $0.24

If you've been keeping up with the bio-pharmaceutical world, you already know that Propanc Biopharma, Inc. (PPCB) is navigating a new frontier in cancer therapy treatment. Their FDA Orphan Drug Designated pancreatic cancer therapy, PRP, is an intravenous combination of two pancreatic proenzymes. PRP targets tumors to prevent recurrence and metastasis, which is the main cause of patient death from cancer.

Just recently, PPCB published a press release "Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies." In this press release PPCB's CEO, James Nathanielsz, stated "We are very pleased with the progress of the purification and characterization of the two key active components for PRP, trypsinogen and chymotrypsinogen, and we're now moving into the Good Manufacturing Practice (GMP) phase of the manufacturing process, to ensure the IMP meets the strict guidelines for pharmaceutical use in humans."

The press released information on all activities related to the commencement of their First-In-Human (FIH) study on PRP. They are making significant progress towards the full scale manufacture of the investigational medicinal product (IMP) PRP. The full scale manufacture of PRP is a key step in order to submit the Company's first clinical trial application, expected in early 2018. Additionally, PPCB is preparing the regulatory documentation for a supporting clinical trial application and an Orphan Drug Designation (ODD) application to the FDA for the treatment of ovarian cancer.

Kura Oncology, Inc. (NASDAQ: KURA)

Market Cap: $359.93M, Current Share Price: $13.50

KURA is a clinical-stage biopharmaceutical company, and like PPCB, focused on treating cancer. They saw its shares double earlier today after the firm announced results from its mid-stage trial in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).

NewLink Genetics Corporation (NASDAQ: NLNK)

Market Cap: $538.32M, current share price: 18.27

NLNK a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel immuno-oncology product candidates with the aim to improve the lives of patients suffering from cancer. NLNK released updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics' IDO pathway inhibitor, in combination with the PD-1 pathway inhibitor, KEYTRUDA (pembrolizumab) earlier this week.

Stemline Therapeutics, Inc. (NASDAQ: STML)

Market cap: $271.8M, Current Share Price: $10.75

STML, a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced the presentation of clinical data from the ongoing SL-801 Phase 1 trial in patients with advanced solid tumors. The data was presented at the European Society of Medical Oncology (ESMO) Annual Congress 2017 in Madrid, Spain.

Verastem, Inc. (NASDAQ: VSTM)

Market Cap: $200.129M, Current Share Price: $5.34

VSTM is a clinical stage biopharmaceutical company also focuses on discovering and developing drugs to improve outcomes for patients with cancer. Verastem, Inc.'s shares exploded on Wednesday (9/6/17) and closed the day up 28.13%. The stock hit a new 52-week high of $5.55 yesterday and traded nearly 21 million shares compared to an average of just about 970,000. This was after announcing the expansion of its duvelisib development program to include peripheral t-cell lymphoma upon receiving fast track designation by the FDA.

Content Provided By: Microcap Speculators

Email: [e-mail]

Phone: [phone]

Website: http://microcapspeculators.com/